Results 221 to 230 of about 12,024,061 (386)
Detection of the Linac Jaw face angle misalignment using high energy electron beam symmetry. [PDF]
J Appl Clin Med PhysGao S, Cibrian A, Ohrt J, Balter P.
europepmc +1 more source
Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA
Molecular Oncology, EarlyView.Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson +2 more
wiley +1 more source
Transit Traditional Face-to-Face Teaching to Online Teaching during the Outbreak of COVID-2019 [PDF]
, 2020 Han Wan +3 more
openalex +1 more source
Attentional capture by real and illusory faces: a failure to replicate. [PDF]
Psychol ResMiti F +3 more
europepmc +1 more source
Two-dimensional PCA: a new approach to appearance-based face representation and recognition
IEEE Transactions on Pattern Analysis and Machine Intelligence, 2004 Jian Yang +3 more
semanticscholar +1 more source
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
Molecular Oncology, EarlyView.CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
Career Barriers Faced by Turkish Women Academics: Support for What? [PDF]
, 2018 Ayşen Bakioğlu, Nilüfer Ülker
openalex +1 more source
Low-resolution driver face recognition based on super-resolution and triplet loss. [PDF]
Sci RepZhang Z, Sun B, Liang J, He H, Qiao D.
europepmc +1 more source
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source